Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005171-40
    Sponsor's Protocol Code Number:1366-0029
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-03-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2021-005171-40
    A.3Full title of the trial
    Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis
    Etude randomisée, en ouvert et en groupe parallèle pour évaluer les effets du BI 685509 administré par voie orale seul ou en combinaison avec de l’empagliflozine sur l’hypertension portale après 8 semaines de traitement chez des patients atteints d’hypertension portale cliniquement significative (HPCS) dans la cirrhose compensée.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)
    Une étude pour tester si le BI 685509 seul ou en combinaison avec de l’empagliflozine aident les personnes atteintes de cirrhose du foie causée par une hépatite virale ou par une stéatohépatite non alcoolique (NASH) et ayant une pression sanguine élevée dans la veine porte (vaisseau principal allant au foie).
    A.4.1Sponsor's protocol code number1366-0029
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBoehringer-Ingelheim France
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBoehringer Ingelheim France
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBoehringer Ingelheim Pharma GmbH & Co. KG
    B.5.2Functional name of contact pointCT Disclosure & Data Transparency
    B.5.3 Address:
    B.5.3.1Street AddressBinger Strasse 173
    B.5.3.2Town/ cityIngelheim am Rhein
    B.5.3.3Post code55216
    B.5.3.4CountryGermany
    B.5.4Telephone number+498002430127
    B.5.5Fax number+498008217119
    B.5.6E-mailclintriage.rdg@boehringer-ingelheim.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBI 685509
    D.3.2Product code BI 685509
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone yet
    D.3.9.3Other descriptive nameBI 685509
    D.3.9.4EV Substance CodeSUB218320
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Jardiance ®
    D.2.1.1.2Name of the Marketing Authorisation holderBoehringer Ingelheim International GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameJardiance ®
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEmpagliflozin
    D.3.9.1CAS number 864070-44-0
    D.3.9.3Other descriptive nameEmpagliflozin
    D.3.9.4EV Substance CodeSUB35915
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBI 685509
    D.3.2Product code BI 685509
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone yet
    D.3.9.3Other descriptive nameBI 685509
    D.3.9.4EV Substance CodeSUB218320
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBI 685509
    D.3.2Product code BI 685509
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone yet
    D.3.9.3Other descriptive nameBI 685509
    D.3.9.4EV Substance CodeSUB218320
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    portal hypertension
    Hypertension portale
    E.1.1.1Medical condition in easily understood language
    hypertension
    Hypertension
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10036200
    E.1.2Term Portal hypertension
    E.1.2System Organ Class 10019805 - Hepatobiliary disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The trial will investigate the safety and tolerability of BI 685509 in patients with CSPH in compensated cirrhosis due to HBV, HCV and NASH with or without T2DM and the combination of BI 685509 and empagliflozin in patients with CSPH in compensated cirrhosis due to NASH with T2DM, on top of standard of care respectively.
    The primary objective is to estimate the percentage change in HVPG from baseline measured after 8 weeks. The primary analysis will be made for treated patients with baseline HVPG measurements (Full Analysis Set, FAS) as if all patients took treatment for the duration of the trial.
    Cet essai compare la sécurité et la tolérance du BI 685509 chez les patients atteints d’HPCS dans la cirrhose compensée due à une hépatite virale B, une hépatite virale C et à la NASH avec ou sans diabète de type 2 et celles de l'association du BI 685509 et de l'empagliflozine chez les patients atteints d’HPCS dans la cirrhose compensée due à la NASH avec diabète de type 2, en plus respectivement des soins standard. L'objectif principal est d'estimer le pourcentage de variation du GPVH après 8 semaines de traitement par rapport à la valeur de base.
    E.2.2Secondary objectives of the trial
    Safety and tolerability will also be investigated.
    La sécurité et la tolérance vont également être évaluées.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
    2. Male or female who is ≥ 18 (or who is of legal age in countries where that is greater than 18) and ≤ 75 years old at screening (Visit 1a)
    3. Clinical signs of CSPH as described by either one of the points below. Each trial patient must have a gastroscopy during the screening period (Visit 1b) or within 3 months prior to screening (Visit 1b).
    - documented endoscopic proof of oesophageal varices and / or gastric varices at
    screening (Visit 1b) or within 3 months prior to screening (Visit 1b)
    - documented endoscopic-treated oesophageal varices as preventative treatment
    4. CSPH defined as baseline HVPG ≥ 10 mmHg (measured at Visit 1c), based on a local interpretation of the pressure tracing
    5. Diagnosis of compensated cirrhosis due to HCV, HBV, or NASH with or without T2DM. Diagnosis of cirrhosis must be based on histology (historical data is acceptable) or on clinical evidence of cirrhosis (e.g. platelet count < 150 x 109/L [150 x 103/μL], nodular liver surface on imaging or splenomegaly etc.) Diagnosis of NASH based on either
    i. Current or historic histological diagnosis of NASH OR steatosis
    OR
    ii. Clinical diagnosis of NASH based on historic or current imaging diagnosis of fatty liver (Fibroscan, US, MRI, CT) AND at least 2 current or historic comorbidities of the metabolic syndrome (overweight/obesity, T2DM, hypertension, hyperlipidemia)
    6. Willing and able to undergo HVPG measurements per protocol (based on Investigator judgement)
    7. If receiving statins must be on a stable dose for at least 3 months prior to screening (Visit 1b), with no planned dose change throughout the trial
    8. If receiving treatment with NSBBs or carvedilol must be on a stable dose for at least 3 months prior to screening (Visit 1b), with no planned dose change throughout the trial

    Further criteria apply.
    1. Consentement éclairé daté et signé en accord avec les Bonnes Pratiques Cliniques (BPC) et la législation locale en vigueur avant l’admission à l’étude.
    2. Patients masculins ou féminins âgés de 18 ans à 75 ans inclus à la sélection (visite 1a).
    3. Signes cliniques d’HPCS tels que décrits par l'un des points ci-dessous. Chaque patient de l'essai doit subir une gastroscopie pendant la période de sélection (visite 1b) ou dans les 3 mois précédant la sélection (visite 1b). Pour plus de détails, se reporter à la section 5.2.5.2 du protocole.
    - preuve endoscopique documentée de présence de varices œsophagiennes et/ou de varices gastriques à la sélection (visite 1b) ou dans les 3 mois précédant la sélection (visite 1b)
    - présence de varices œsophagiennes documentées traitées par endoscopie comme traitement préventif.
    4. HPCS définie comme un GPVH initial ≥ 10 mmHg (mesuré à la visite 1c) sur la base d’une interprétation locale du tracé de la pression (voir section 5.1.1 du protocole pour plus de détails).
    5. Diagnostic de cirrhose compensée due à une hépatite virale B, une hépatite virale C ou à la NASH avec ou sans diabète de type 2. Le diagnostic de la cirrhose doit être basé sur l'histologie (les données historiques sont acceptables) ou sur des preuves cliniques de cirrhose [par exemple : numération plaquettaire < 150 x 109/L (150 x 103/µL), surface nodulaire du foie à l'imagerie ou splénomégalie, etc…].
    Diagnostic de NASH basé soit sur :
    i. un diagnostic histologique actuel ou historique de NASH OU de stéatose
    OU
    ii. un diagnostic clinique de NASH basé sur un diagnostic d'imagerie historique ou actuel de stéatose hépatique (FibroScan®, ultrason, IRM, scanner) ET au moins 2 comorbidités actuelles ou historiques du syndrome métabolique (surpoids/obésité, diabète de type 2, hypertension, hyperlipidémie).
    6. Patient disposé et en capacité de subir des mesures du GPVH selon le protocole (basé sur le jugement de l’investigateur).
    7. Si le patient est traité par statines, celles-ci doivent être à une dose stable pendant au moins 3 mois avant la sélection (visite 1b) et sans modification de dose prévue tout au long de l'essai.
    8. Si le patient est traité par bêtabloquants non sélectifs (BBNS) ou par carvédilol, ceux-ci doivent être à une dose stable pendant au moins 3 mois avant la sélection (visite 1b) et sans changement de dose prévu tout au long de l'essai.
    D'autres critères s'appliquent
    E.4Principal exclusion criteria
    1. Previous clinically significant decompensation events (e.g. ascites [more than perihepatic ascites], VH and / or overt / apparent HE)
    2. History of other forms of chronic liver disease (e.g. alcohol-related liver disease (ARLD), autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilson’s disease, haemachromatosis, alpha-1 antitrypsin [A1At] deficiency)
    3. Patients without adequate treatment for HBV, HCV or NASH as per local guidance (e.g. antiviral therapy for chronic HBV or HCV infection or lifestyle modification in NASH)
    - if received curative anti-viral therapy for HCV, no sustained virological response (SVR) or SVR sustained for less than 2 years prior to screening or if HCV RNA detectable
    - If receiving anti-viral therapy for HBV, less than 6 months on a stable dose prior to screening, with planned dose change during the trial or HBV DNA detectable
    - Weight change ≥ 5% within 6 months prior screening
    4. Must take, or wishes to continue the intake of, restricted concomitant therapy or any concomitant therapy considered likely (based on Investigator judgement) to interfere with the safe conduct of the trial
    5. SBP < 100 mmHg and DBP < 70 mmHg at screening (Visit 1a)
    6. Model of End-stage Liver Disease (MELD) score of > 15 at screening (Visit 1a), calculated by the central laboratory
    7. Hepatic impairment defined as a Child-Turcotte-Pugh score ≥ B8 at screening (Visit 1a), calculated by the site, using central laboratory results
    8. ALT or AST > 5 times upper limit of normal (ULN) at screening (Visit 1a), measured by the central laboratory

    Further criteria apply.
    1. Événements antérieurs de décompensation cliniquement significatifs [par exemple : une ascite (plus qu’une ascite péri-hépatique), une hémorragie variqueuse et/ou une encéphalopathie hépatique manifeste ou apparente].
    2. Antécédents d’autres formes de pathologie hépatique chronique (par exemple : maladie du foie liée à l’alcool, maladie hépatique auto-immune, sclérose biliaire primitive, cholangite sclérosante primitive, maladie de Wilson, hémochromatose, déficit en alpha 1-antitrypsine).
    3. Patient sans traitement adéquat pour le virus de l’hépatite B, le virus de l’hépatite C ou la NASH selon les recommandations locales (par exemple, traitement antiviral pour l’infection chronique par le virus de l’hépatite B ou C ou modification du mode de vie dans la NASH).
    • En cas de traitement antiviral curatif contre le virus de l’hépatite C, sans réponse virologique soutenue (RVS) ou avec RVS depuis moins de 2 ans avant la sélection ou en cas d’ARN du virus de l’hépatite C détectable.
    • En cas de traitement antiviral contre le virus de l’hépatite B, depuis moins de 6 mois à une dose stable avant la sélection, avec un changement de dose prévu au cours de l'essai ou avec un ADN du virus de l’hépatite B détectable.
    • Changement de poids ≥ 5 % dans les 6 mois qui précèdent la sélection.
    4. Patient devant prendre ou souhaitant continuer la prise d'un traitement concomitant restreint (se reporter à la section 4.2.2.1 du protocole) ou de tout traitement concomitant considéré comme susceptible (sur la base du jugement de l'investigateur) d'interférer avec le bon déroulement de l'essai.
    5. PAS < 100 mmHg et PAD < 70 mmHg à la sélection (visite 1a).
    6. Score de MELD (Model for End-stage Liver Disease) > 15 à la sélection (visite 1a), calculé par le laboratoire centralisé.
    7. Insuffisance hépatique définie par un score de Child-Turcotte-Pugh ≥ B8 à la sélection (Visite 1a), calculé par le centre, à partir des résultats du laboratoire centralisé (voir annexe 10.3 du protocole).
    8. ALAT ou ASAT > 5 x LSN (limite supérieure de la normale) à la sélection (visite 1a), mesurés par le laboratoire centralisé.
    D'autres critères s'appliquent
    E.5 End points
    E.5.1Primary end point(s)
    1) Percentage change in HVPG from baseline (measured in mmHg) after 8 weeks of treatment
    1) Pourcentage du gradient de pression veineuse hépatique (GPVH) par rapport à la valeur initiale (mesurée en mmHg) après 8 semaines de traitement.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1) 8 weeks
    1) 8 semaines
    E.5.2Secondary end point(s)
    1) occurrence of a response, which is defined as > 10% reduction from baseline HVPG (measured in mmHg) after 8 weeks of treatment
    2) occurrence of one or more decompensation events (i.e. ascites, VH, and / or overt HE) during the 8-week treatment period
    3) occurrence of CTCAE grade 3 (or higher) hypotension or syncope based on Investigator judgement, during the 8-week treatment period
    4) occurrence of discontinuation due to hypotension or syncope during the 8-week treatment period
    1) Survenue d’une réponse, qui est définie comme > 10% de réduction par rapport à la valeur initiale du GPVH (mesurée en mmHg) après 8 semaines de traitement ;
    2) Survenue d’un ou plusieurs évènements de décompensation (c’est-à-dire ascite, hémorragie variqueuse et/ou encéphalopathie hépatique manifeste) au cours de la période de traitement de 8 semaines ;
    3) Survenue d’une hypotension ou d’une syncope de grade CTCAE 3 (ou supérieur) selon le jugement de l’investigateur, au cours de la période de traitement de 8 semaines;
    4) Survenue d’un arrêt dû à une hypotension ou à une syncope au cours de la période de traitement de 8 semaines
    E.5.2.1Timepoint(s) of evaluation of this end point
    1) 8 weeks
    2) 8 weeks
    3) 8 weeks
    4) 8 weeks
    1) 8 semaines
    2) 8 semaines
    3) 8 semaines
    4) 8 seamines
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA23
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Canada
    China
    Israel
    Japan
    Singapore
    United States
    Austria
    Belgium
    Denmark
    France
    Germany
    Italy
    United Kingdom
    Netherlands
    Spain
    Switzerland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Dernière visite du dernier patient
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 60
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 45
    F.4.2.2In the whole clinical trial 80
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Aucun
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-05-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-05-06
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 08:46:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA